Description

The American Association of Blood Banks (AABB) prohibits the addition of drugs to blood products and makes recommendations for infusing blood in lines running other infusates. This prohibition is intended to prevent serious adverse effects to the patient.


 

Drug or Drug Additive

Consequence

propylene glycol or other solvents

hemolysis of red blood cells, drug precipitates

very high or very low pH

hemolysis of red blood cells

poorly soluble medications

drug precipitates

 

 

IV Solution

Consequence

5% dextrose in water

clumping and hemolysis of red blood cells

hypotonic or hypertonic solutions

hemolysis of red blood cells

calcium containing (Ringer's lactate, others)

blood clots

total parenteral nutrition (TPN)

very hypertonic, with red cell hemolysis

 

Other problems with adding or infusing drugs with red blood cell products:

(1) If an adverse reaction develops, it may be impossible to distinguish an adverse drug reaction from a transfusion reaction.

(2) If the blood product is discontinued prematurely, then it may be difficult to determine how much of a drug was given (although this can be estimated if the pre- and post-transfusion volume of the blood product is recorded).

(3) Bacterial contamination.

(4) Drugs added or infused with platelet concentrates may cause platelet clumping.

(5) If filters are not used in the infusion set-up then microembolization may occur.

 

Recommendations:

(1) Normal saline (0.9% sodium chloride) is the preferred solution for diluting or infusing with blood cell products.

(2) If red blood cells are infused through an existing infusion set, close off all other solutions and run normal saline through the line for at least 15 minutes (preferably 30 minutes) before infusing blood through the line.

(3) Isotonic calcium-free electrolyte solutions may be used in place of normal saline, but the suitability should be verified prior to use.

 


To read more or access our algorithms and calculators, please log in or register.